AFFX Affymetrix, Inc.

Affymetrix, Inc. (Nasdaq:AFFX) today announced that Giulia C. Kennedy, Ph.D., Senior Director of Genomics Collaborations, will provide an overview of applications of Affymetrix technology in oncology research and clinical studies at the Baird 2006 Focus on Oncology Conference in New York, NY. A live webcast of the presentation will take place at 9:35 a.m. ET on Wednesday August 2, 2006. An archived webcast will be available for 30 days. To access the live webcast or archived presentation, find the "Investors" link in the "Resources for" drop-down menu on www.affymetrix.com. About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix, Inc.